InvestorsHub Logo
Followers 103
Posts 13746
Boards Moderated 1
Alias Born 01/23/2004

Re: bobw1951 post# 19880

Thursday, 05/25/2023 9:02:51 PM

Thursday, May 25, 2023 9:02:51 PM

Post# of 20024
Let's look at what is right in front of us.

The company was set to pay 15 million dollars to Coretag to have Coretag take the ticker off Joe's hands and dilute current shareholders 25 to 1.

Telling shareholders that the CCA technology in hand is considered 15 million dollars less then worthless.

What an interesting Ponzi Scheme.

Here you have Coretg Holding owning two Subsidiaries. Coretg Theraoeutics AG and Actinocore GMBH.
Coretg Holdings transferred all its license and intellectual properties based on its proprietary
NTPT for the development of its targeted radiotherapy to Actinocore GmbH,
Based on what is in the filings Coretg Theraoeutics AG has nothing of value.

So we have one subsidiary Coretg Theraoeutics AG of Coretg Holding signing a deal with Coretg Holding to acquire Coretg Holding other subsidiary Actinocore GmbH,.

NDTP is acquiring Coretg Theraoeutics AG .for 100,000 share of 25-1 post split stock.

Once Coretg Theraoeutics AG .is acquired, NDTP will pay Coretg Holding additional Common Stock Post Reverse Split in the Company as the additional purchase price for the acquisition
of the Licensee Company by the Target Company at a valuation of One ($1.00) US Dollar per shares in
accordance with the Valuation Report (One Hundred Million ($100,000,000.00) and Four Hundred Million ($400,000,000.00 or 100,000,000 to 400,000,0000 shares) so that Cortg holding subsidiary Coretg Therapeutics AG can purchase Cortg holding subsidiary Actinocore GmbH.

In addition Fifteen Million ($15,000,000.00) US Dollars will be paid by the Company in cash to Coretag Holding when the Company is funded and whereby the Coretag Holding will become the control shareholder(s) in the Company,

So in the end Cortg Holding ends up with NDTP while still controlling both its subsidiaries and being 15 million richer while NDTP shareholders get screwed with a 25 to 1 reverse split and 100,000,000 to 400,000,000 shares of dilutions and having NDTP fronting the bill so that Cortg Therapeutics AG can purchase Actinocore GmbH. .